H.C. Wainwright analyst Joseph Pantginis has maintained their bullish stance on ESPR stock, giving a Buy rating yesterday.
Joseph Pantginis has given his Buy rating due to a combination of factors related to Esperion’s strategic development plans and pipeline expansion. The company’s recent R&D Day highlighted its commitment to broadening its early-stage development pipeline, particularly with a new program targeting primary sclerosing cholangitis (PSC). This initiative leverages Esperion’s expertise in ATP citrate lyase (ACLY) biology, addressing high unmet medical needs and expanding the potential applications of their ACLY inhibitors.
Esperion’s current product, bempedoic acid, is the only commercially available ACLY inhibitor, specifically designed to lower LDL-cholesterol levels. The company’s next-generation ACLY inhibitors aim to target various liver cell types, potentially addressing broader metabolic dysregulation issues. This strategic focus on ACLY as a modulator of liver cell dysfunction beyond cholesterol metabolism positions Esperion to capitalize on significant market opportunities, supporting Pantginis’s optimistic outlook and Buy rating.
In another report released yesterday, Needham also maintained a Buy rating on the stock with a $5.00 price target.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ESPR in relation to earlier this year.